A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
← catalyst calendarSponsored by TScan Therapeutics, Inc. (industry) · TCRX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,150estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-26 | actual | When the study began enrolling |
| Primary completion | 2026-01-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Head and Neck Cancer
- Cervical Cancer
- Non Small Cell Lung Cancer
- HPV16 Related Cancers
- Sarcoma
- Uveal Melanoma
- NUT Carcinoma
Intervention
- Diagnostic test: Tumor and HLA Profiling
Primary outcome
what the primary-completion date above is the date OFFrequency of subjects with TAA expression, HLA typing and HLA loss.
measured 3 years
Permalink · TCRX's whole pipeline · Catalyst calendar · Every registered study · What changed